دورية أكاديمية
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
| العنوان: | Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial |
|---|---|
| المؤلفون: | Cremolini C., Antoniotti C., Rossini D., Lonardi S., Loupakis F., Pietrantonio F., Bordonaro R., Latiano T. P., Tamburini E., Santini D., Passardi A., Marmorino F., Grande R., Aprile G., Zaniboni A., Murgioni S., Granetto C., Buonadonna A., Moretto R., Corallo S., Cordio S., Antonuzzo L., Tomasello G., Masi G., Ronzoni M., Di Donato S., Carlomagno C., Clavarezza M., Ritorto G., Mambrini A., Roselli M., Cupini S., Mammoliti S., Fenocchio E., Corgna E., Zagonel V., Fontanini G., Ugolini C., Boni L., Falcone A., De Braud F. G. M., Maiello E., Frassineti G. L., Gamucci T., Di Costanzo F., Gianni L., Racca P., Allegrini G., Sobrero A., Aglietta M., Cortesi E., Corsi D. C., Ballestrero A., Bonetti A., Di Clemente F., Ruggeri E., Ciardiello F., Benasso M., Vitello S., Cinieri S., Mosconi S., Silvestris N., Frassoldati A., Bertolini A., Tortora G., Bengala C., Ferrari D., Ardizzoia A., Milandri C., Chiara S., Romano G., Miraglia S., Scaltriti L., Pucci F., Blasi L., Brugnatelli S., Fioretto L., Ribecco A. S., Longarini R., Frisinghelli M., Banzi M. |
| المساهمون: | Cremolini, C., Antoniotti, C., Rossini, D., Lonardi, S., Loupakis, F., Pietrantonio, F., Bordonaro, R., Latiano, T. P., Tamburini, E., Santini, D., Passardi, A., Marmorino, F., Grande, R., Aprile, G., Zaniboni, A., Murgioni, S., Granetto, C., Buonadonna, A., Moretto, R., Corallo, S., Cordio, S., Antonuzzo, L., Tomasello, G., Masi, G., Ronzoni, M., Di Donato, S., Carlomagno, C., Clavarezza, M., Ritorto, G., Mambrini, A., Roselli, M., Cupini, S., Mammoliti, S., Fenocchio, E., Corgna, E., Zagonel, V., Fontanini, G., Ugolini, C., Boni, L., Falcone, A., De Braud, F. G. M., Maiello, E., Frassineti, G. L., Gamucci, T., Di Costanzo, F., Gianni, L., Racca, P., Allegrini, G., Sobrero, A., Aglietta, M., Cortesi, E., Corsi, D. C., Ballestrero, A., Bonetti, A., Di Clemente, F., Ruggeri, E., Ciardiello, F., Benasso, M., Vitello, S., Cinieri, S., Mosconi, S., Silvestris, N., Frassoldati, A., Bertolini, A., Tortora, G., Bengala, C., Ferrari, D., Ardizzoia, A., Milandri, C., Chiara, S., Romano, G., Miraglia, S., Scaltriti, L., Pucci, F., Blasi, L., Brugnatelli, S., Fioretto, L., Ribecco, A. S., Longarini, R., Frisinghelli, M., Banzi, M. |
| سنة النشر: | 2020 |
| المجموعة: | Università degli Studi della Campania "Luigi Vanvitelli": CINECA IRIS V: |
| مصطلحات موضوعية: | Adolescent, Adult, Aged, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocol, Bevacizumab, Camptothecin, Colorectal Neoplasm, Disease Progression, Female, Fluorouracil, Human, Leucovorin, Male, Middle Aged, Neoplasm Metastasi, Organoplatinum Compound, Young Adult |
| الوصف: | Background: The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab showed improved outcomes for patients with metastatic colorectal cancer, compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab. However, the actual benefit of the upfront exposure to the three cytotoxic drugs compared with a preplanned sequential strategy of doublets was not clear, and neither was the feasibility or efficacy of therapies after disease progression. We aimed to compare a preplanned strategy of upfront FOLFOXIRI followed by the reintroduction of the same regimen after disease progression versus a sequence of mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) and FOLFIRI doublets, in combination with bevacizumab. Methods: TRIBE2 was an open-label, phase 3, randomised study of patients aged 18–75 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 2, with unresectable, previously untreated metastatic colorectal cancer, recruited from 58 Italian oncology units. Patients were stratified according to centre, ECOG performance status, primary tumour location, and previous adjuvant chemotherapy. A randomisation system incorporating a minimisation algorithm was used to randomly assign patients (1:1) via a masked web-based allocation procedure to two different treatment strategies. In the control group, patients received first-line mFOLFOX6 (85 mg/m2 of intravenous oxaliplatin concurrently with 200 mg/m2 of leucovorin over 120 min; 400 mg/m2 intravenous bolus of fluorouracil; 2400 mg/m2 continuous infusion of fluorouracil for 48 h) plus bevacizumab (5 mg/kg intravenously over 30 min) followed by FOLFIRI (180 mg/m2 of intravenous irinotecan over 120 min concurrently with 200 mg/m2 of leucovorin; 400 mg/m2 intravenous bolus of fluorouracil; 2400 mg/m2 continuous infusion of fluorouracil for 48 h) plus bevacizumab after disease progression. In the experimental group, patients received FOLFOXIRI (165 mg/m2 of intravenous irinotecan over 60 min; 85 ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/32164906; info:eu-repo/semantics/altIdentifier/wos/WOS:000522625000026; volume:21; issue:4; firstpage:497; lastpage:507; numberofpages:11; journal:THE LANCET ONCOLOGY; http://hdl.handle.net/11591/432744Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85082493423 |
| DOI: | 10.1016/S1470-2045(19)30862-9 |
| الإتاحة: | https://doi.org/10.1016/S1470-2045Test(19)30862-9 http://hdl.handle.net/11591/432744Test |
| رقم الانضمام: | edsbas.D14E0221 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/S1470-2045(19)30862-9 |
|---|